GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of Cutaneous Pathology, Wiley, Vol. 49, No. 5 ( 2022-05), p. 438-441
    Abstract: The oncofetal protein insulin‐like growth factor 2 mRNA binding protein‐3 (IMP3) is expressed in various cancers. In this study, we examined the diagnostic utility of IMP3 immunohistochemistry in the context of intravascular large B‐cell lymphoma (IVL). Methods We obtained 25 skin biopsy (SB) specimens diagnosed as IVL and nine IVL‐negative SB specimens from 27 IVL patients. Additionally, 27 negative SB specimens from 26 non‐IVL patients were obtained from our pathology archives. We performed IMP3 immunohistochemistry on these 61 SB specimens, considering IMP3 expression in any mononuclear cell as positive. In selected cases, triple immunostaining for IMP3, PAX5, and CD34 was performed to analyze the origin and location of IMP3‐positive cells. Results IMP3 was expressed in most intravascular lymphoma cells in all the 25 SB specimens diagnosed as IVL. Furthermore, our evaluation revealed the presence of intravascular IMP3‐positive B‐cells in five of the nine negative SB specimens from IVL patients; however, this was not observed in the 27 SB specimens from non‐IVL patients. Conclusion IMP3 was expressed in most IVL cells, and IMP3 immunohistochemistry could serve as a sensitive diagnostic aid for detecting IVL cells in SB.
    Type of Medium: Online Resource
    ISSN: 0303-6987 , 1600-0560
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2018100-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Wiley ; 2022
    In:  Journal of Cutaneous Pathology Vol. 49, No. 12 ( 2022-12), p. 1011-1014
    In: Journal of Cutaneous Pathology, Wiley, Vol. 49, No. 12 ( 2022-12), p. 1011-1014
    Type of Medium: Online Resource
    ISSN: 0303-6987 , 1600-0560
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2018100-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Transplantation, Ovid Technologies (Wolters Kluwer Health), Vol. 101, No. 5 ( 2017-05), p. 1074-1083
    Type of Medium: Online Resource
    ISSN: 0041-1337
    RVK:
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2017
    detail.hit.zdb_id: 2035395-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Journal of Hepato-Biliary-Pancreatic Sciences, Wiley, Vol. 30, No. 7 ( 2023-07), p. 882-892
    Abstract: This experimental study in rats aimed to investigate the impact of very early introduction (within 3 h) of everolimus (EVR) + reduced‐tacrolimus (TAC) after partial liver transplantation (LT) on liver regeneration, rejection, and survival. Methods Based on appropriate dose of EVR + reduced‐TAC in 70% hepatectomy (Experiment 1), allogeneic 30% partial LT (Experiment 2) and whole LT (Experiment 3) were performed. Results After partial LT in EVR + reduced‐TAC therapy, restoration of liver graft weight (to that of the whole liver) was delayed compared with standard dose TAC monotherapy (standard‐TAC) on day 3 (59.3% vs. 72.9%; p   〈  .001) and 14 (88.1% vs. 95.5%; p  = .01). Survival was 75%, which was not as high as the value of 100% observed for standard‐TAC, because neither infection nor rejection could be prevented. By contrast, survival after whole LT was 100% as neither infection nor rejection occurred. Conclusions The very early introduction of EVR + reduced‐TAC after partial LT delayed liver regeneration, and made it difficult to manage the dose required to suppress both infection and rejection. On the other hand, EVR + reduced‐TAC could be introduced safely very early after whole LT.
    Type of Medium: Online Resource
    ISSN: 1868-6974 , 1868-6982
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2536390-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Medicine, Wiley, Vol. 6, No. 4 ( 2017-04), p. 845-856
    Abstract: Carcinoembryonic antigen‐related cell adhesion molecule 1 ( CEACAM 1) is expressed in a number of tumor cell types. The immunoreceptor tyrosine‐based inhibitory motif ( ITIM )‐containing isoforms of this molecule which possess a long cytoplasmic tail ( CEACAM 1‐L) generally play inhibitory roles in cell function by interacting with Src homology 2 domain‐containing tyrosine phosphatase ( SHP )‐1 and/or SHP ‐2. Src family kinases ( SFK s) are also known to bind to and phosphorylate CEACAM 1‐L isoforms. Here, we report that CEACAM 1 was uniquely expressed at high levels in both human neoplastic mast cells (mastocytosis) and medullary thyroid carcinoma cell ( MTC ) lines, when compared with their expression in nonneoplastic mast cells or nonneoplastic C cells. This expression was mainly derived from CEACAM 1‐L isoforms based upon assessment of CEACAM 1 mRNA expression. CEACAM 1 knockdown upregulated cell growth of HMC 1.2 cells harboring KIT mutations detected in clinical mastocytosis, whereas downregulated the growth of TT cells harboring RET mutations detected in clinical MTC s. Immunoblotting, ELISA and immunoprecipitaion analysis showed that activated SHP ‐1 is preferentially associated with CEACAM 1 in HMC 1.2 cells harboring KIT mutations, whereas Src family kinases ( SFK s) are preferentially associated with CEACAM 1 in TT cells harboring RET mutations. These studies suggest that the dominantly interacting proteins SHP 1 or SFK determine whether CEACAM 1‐L displays a positive or negative role in tumor cells.
    Type of Medium: Online Resource
    ISSN: 2045-7634 , 2045-7634
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2017
    detail.hit.zdb_id: 2659751-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 127, No. 5 ( 2016-02-04), p. 596-604
    Abstract: RHOA mutations are common in ATLL and show a unique distribution compared with other T-cell lymphomas. Depending on patients, functionally distinct RHOA mutations are clonally selected and involved in the pathogenesis of ATLL.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Immunology Research, American Association for Cancer Research (AACR), Vol. 3, No. 8 ( 2015-08-01), p. 871-880
    Abstract: The killer-cell Ig-like receptor (KIR) 2DL4 (CD158d) acts as a receptor for human leukocyte antigen (HLA)-G and is expressed on almost all human natural killer (NK) cells. The expression and function of KIR2DL4 in other hematopoietic cells is poorly understood. Here, we focused on human mast cells, which exhibit cytotoxic activity similar to that of NK cells. KIR2DL4 was detected in all examined human cultured mast cells established from peripheral blood derived from healthy volunteers (PB-mast), the human mast cell line LAD2, and human nonneoplastic mast cells, including those on pathologic specimens. An agonistic antibody against KIR2DL4 decreased KIT-mediated and IgE-triggered responses, and enhanced the granzyme B production by PB-mast and LAD2 cells, by activating Src homology 2–containing protein tyrosine phosphatase (SHP-2). Next, we performed a coculture assay between LAD2 cells and the HLA-G+ cancer cells, MCF-7 and JEG-3, and showed that KIR2DL4 on LAD2 cells enhanced MMP-9 production and the invasive activity of both cell lines via HLA-G. Immunohistochemical analysis revealed that the direct interaction between HLA-G+ breast cancer cells and KIR2DL4+ tissue mast cells (observed in 12 of 36 cases; 33.3%) was statistically correlated with the presence of lymph node metastasis or lymph-vascular invasion (observed in 11 of 12 cases; 91.7%; χ2 = 7.439; P & lt; 0.01; degrees of freedom, 1) in the clinical samples. These findings suggest that the KIR2DL4 on human mast cells facilitates HLA-G–expressing cancer invasion and the subsequent metastasis. Cancer Immunol Res; 3(8); 871–80. ©2015 AACR.
    Type of Medium: Online Resource
    ISSN: 2326-6066 , 2326-6074
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2732517-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Nature, Springer Science and Business Media LLC, Vol. 620, No. 7974 ( 2023-08-17), p. 607-614
    Abstract: Recent studies have documented frequent evolution of clones carrying common cancer mutations in apparently normal tissues, which are implicated in cancer development 1–3 . However, our knowledge is still missing with regard to what additional driver events take place in what order, before one or more of these clones in normal tissues ultimately evolve to cancer. Here, using phylogenetic analyses of multiple microdissected samples from both cancer and non-cancer lesions, we show unique evolutionary histories of breast cancers harbouring der(1;16), a common driver alteration found in roughly 20% of breast cancers. The approximate timing of early evolutionary events was estimated from the mutation rate measured in normal epithelial cells. In der(1;16)(+) cancers, the derivative chromosome was acquired from early puberty to late adolescence, followed by the emergence of a common ancestor by the patient’s early 30s, from which both cancer and non-cancer clones evolved. Replacing the pre-existing mammary epithelium in the following years, these clones occupied a large area within the premenopausal breast tissues by the time of cancer diagnosis. Evolution of multiple independent cancer founders from the non-cancer ancestors was common, contributing to intratumour heterogeneity. The number of driver events did not correlate with histology, suggesting the role of local microenvironments and/or epigenetic driver events. A similar evolutionary pattern was also observed in another case evolving from an AKT1 -mutated founder. Taken together, our findings provide new insight into how breast cancer evolves.
    Type of Medium: Online Resource
    ISSN: 0028-0836 , 1476-4687
    RVK:
    RVK:
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 120714-3
    detail.hit.zdb_id: 1413423-8
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2015
    In:  Cancer Research Vol. 75, No. 15_Supplement ( 2015-08-01), p. 2357-2357
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 15_Supplement ( 2015-08-01), p. 2357-2357
    Abstract: Background Antibody therapy such as trastuzumab is imperative for HER2-positive breast cancer patients. Although its antitumor action is not completely understood, the role of immune cells in antibody therapy is indispensable. Neuropilin-1 (NRP1) in monocytes induces high in vitro anti-tumor activity. Here, we showed the role of NRP1 in monocytes in HER2-positive breast cancer, using a tumor-bearing NOD/Shi-SCID, IL-2Rγnull(NOG) mouse model. Experimental procedures A tumor-bearing NOG mouse was made using BT474-sGL containing transfected HER2-positive human breast cancer cell lines that secreted Gaussia luciferase (Gluc). Tumor volumes were measured, using Gluc relative light units (RLUs), in 5 treatment arms (Table). Each arm was allocated 5 NOG mice, randomized by body weight and RLUs. Cytokines released into culture supernatants were determined using human Bio- Plex Cytokine Assay Kits (Bio-Rad, Hercules, CA), according to the manufacturer's instructions. mRNA was measured using TAQMAN array (LifeTechnologies, Carlsbad, CA) gene expression studies, according to the manufacturer's instructions. Results Knockdown of NRP-1 in monocytes impaired anti-tumor activity: After 2 cycles of treatment, RLUs increased significantly from baseline in Arm E, compared with those in Arm D. There was no significant difference between Arms B and E. Knockdown of NRP-1 in monocytes impaired migration activity: Staining for human-specific CD45 revealed that the tumor infiltrating lymphocytes of Arm E decreased compared with those of Arm D; CD45 mRNA was significantly lower in Arm E than in Arm D. Chemokine secretion is regulated by NRP-1: Tumor chemokine (e.g., IP-10, MIP-1α, MIP-1β and RANTES) secretion was significantly decreased due to knockdown of NRP-1. Conclusion Our data suggest that NRP-1-expressing immune cells initiate anti-tumor activity via migration and chemokine secretion. Summary of resultsArmHumanizedTrastuzumabNRP1 KD% change RLU (mean ± SEM)CD45 mRNA relative quantities (mean ± SEM)IP-10 pg/mL (mean ± SEM)MIP-1α pg/mL (mean ± SEM)MIP-1β pg/mL (mean ± SEM)RANTES pg/mL (mean ± SEM)ANoNoNo495 ± 76.00.75 ± 0.3822.2 ± 6.351.16 ± 0.013.51 ± 3.515.36 ± 2.68BNoYesNo49.6 ± 43.20.50 ± 0.2617.1 ± 13.91.20 ± 0.275.75 ± 5.757.87 ± 4.40CYesNoNo566 ± 145504 ± 2421361 ± 4538.31 ± 3.1582.9 ± 43.659.4 ± 42.6DYesYesNo-45.7 ± 12.91650 ± 4055880 ± 26006.43 ± 1.3767.0 ± 13.9171 ± 35.4EYesYesYes46.2 ± 15.4307 ± 121285 ± 73.21.60 ± 0.3010.7 ± 2.3229.7 ± 9.69p value of D vs. Ep & lt; 0.01p = 0.04p = 0.03p & lt; 0.01p & lt; 0.01p & lt; 0.01 Citation Format: Kosuke Kawaguchi, Eiji Suzuki, Isao Kii, Tatsuki R. Kataoka, Masahiro Hirata, Hironori Haga, Masatoshi Hagiwara, Masakazu Toi. Knockdown of neuropilin-1 in monocytes impaired lymphocyte migration and anti-tumor activity in a humanized mouse model. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2357. doi:10.1158/1538-7445.AM2015-2357
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 79, No. 13_Supplement ( 2019-07-01), p. 741-741
    Abstract: [Introduction] Non-malignant proliferative lesions in the breast have been implicated in the development of invasive breast cancer. Previous studies showed that adjacent atypical proliferative lesions and breast cancers shared common genetic alterations, suggesting that these evolved from the same ancestral cell. However, the clonal structure of atypical proliferative lesions and their clonal dynamics during progression to cancer are poorly understood. In this study, we compared genetic profiles of normal ducts, non-malignant proliferative lesions and cancers in the same patients to illustrate the clonal evolution of cancer from a non-malignant epithelial cell. [Methods] Multiple samples were collected from different proliferative lesions within the cancer-borne breast, including invasive cancers, using micro-dissection from formalin-fixed, paraffin-embedded surgical specimens. Somatic mutations and copy number alterations (CNAs) were then evaluated by whole exome sequencing. [Results] A total of 39 samples from 6 premenopausal females carrying estrogen receptor-positive cancers were analyzed, where the samples were obtained from normal ducts (N = 5), non-malignant proliferative lesions (N = 9), and non-invasive (N = 21) and invasive (N = 4) cancers. The number of somatic mutations per sample was ranging from 1 to 311 and increased with pathological disease progression. Two cases with bilateral cancers had a pathogenic germline mutation of either BRCA2 or TP53, where no somatic mutations or CNAs were shared by individual proliferative lesions, suggesting multifocal independent cancerous evolutions. By contrast, in the remaining four unilateral cases, no pathogenic germline mutations were detected, but all proliferative lesions, which were separated by a distance of 7-33 mm, shared one or more driver alterations, such as an AKT1 mutation (UID: KU01), a GATA3 mutation (UID: KU03 and KU06), a CBFB mutation (UID: KU06) and concurrent 1q gain and 16q loss (UID: KU02, KU03 and KU06), while harboring private mutations/CNAs of their own. The analysis of phylogenic trees based on the number of shared mutations predicted an early origin of these founder mutations, which frequently predated decades before the onset of cancer. [Conclusions] Early breast cancer development is thought to be shaped by a simultaneous evolution of multiple precancerous clones. It may be multi-focally initiated by a germline mutation, frequently terminated in bilateral cancers. By contrast, in unilateral cases, cancer clones might be derived from a common ancestral clone, which has acquired a driver founder mutation long before the onset of cancer, and undergo independent evolution, giving rise to multiple proliferative lesions, from which invasive cancer finally evolves. Our findings provide unique insight into the early development of breast cancer. Citation Format: Tomomi Nishimura, Kenichi Yoshida, Yukiko Kawata, Yasuhide Takeuchi, Nobuyuki Kakiuchi, Yusuke Shiozawa, Kosuke Aoki, Masahiro Hirata, Tatsuki R. Kataoka, Takaki Sakurai, Satoko Baba, Yuichi Shiraishi, Kenichi Chiba, Kengo Takeuchi, Hironori Haga, Satoru Miyano, Masakazu Toi, Seishi Ogawa. Clonal evolution of non-malignant proliferative lesions into breast cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 741.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2019
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...